Articles tagged with Cancer Relapse
Researchers at the Buck Institute found that chemotherapy induces widespread cellular senescence, contributing to persistent inflammation and cancer recurrence. Eliminating senescent cells reduced side effects, including fatigue, bone marrow suppression, and toxicity, in mice treated with common chemotherapy drugs.
Researchers found that children with ALL who live in high-poverty areas are substantially more likely to experience early relapse, which is harder to treat. Despite receiving the same treatment, these patients have a higher risk of relapse within 36 months after first achieving complete remission.
Scientists developed a test to identify patients at risk of relapse from non-seminomatous germ cell tumour. The test assessed three features: CXCL12 levels, cancer stem cells, and blood vessel presence. It divided patients into three risk groups, with the low-risk group experiencing high relapse-free survival rates.
A team of scientists analyzed high-throughput sequencing data from 538 CLL patients and identified 44 genes that are frequently mutated in the disease. These mutations, known as driver mutations, affect RNA processing, MYC activity, and MAPK signaling.
A new study by the American Cancer Society found that cancer survivors who currently smoke report fewer negative opinions about smoking and have more barriers to quitting. They are also more likely to be exposed to other smokers, which may contribute to continued smoking.
A study by Children's Hospital of Philadelphia researchers found that cancer-driving mutations in neuroblastoma can be targeted with existing MEK inhibitors, offering hope for improved treatments. The study identified specific mutations on the RAS-MAPK pathway that are sensitive to these drugs.
Researchers discovered that minor clones present at low levels in leukemia cells often drive relapse, contradicting the assumption that mutated cells with more mutations are more likely to survive therapy. The study's findings have implications for monitoring patients in remission and detecting signs of relapse.
Researchers propose epigenetic drugs to treat cancer resistance and relapse by modifying gene expression. Studies suggest epigenetic changes contribute to cancer progenitor cell formation, drug resistance, and relapse.
Researchers at NYU Langone are leading a $6.25 million, five-year research initiative to find targeted treatments for children with acute lymphoblastic leukemia (ALL), the most common form of childhood cancer. The project aims to improve the cure rate and reduce mortality rates among ALL patients.
Researchers found that active and passive distribution methods may not have reached the intended audience, highlighting the need for culturally relevant tobacco information in Spanish. The study's findings suggest that alternative distribution strategies could improve the reach of relapse prevention materials.
Researchers at BUSM propose a new epigenetic hypothesis linked to tumor production and suggest epigenetic drug treatments could be beneficial in treating cancers. They explore the role of DNA methylation and demethylation enzymes in regulating gene expression, suggesting potential therapeutic targets.
Researchers at Mercer University are developing an oral vaccine that can be delivered in spherical bead-like particles to enhance innate immune recognition, offering a cost-effective alternative to current options. The vaccine aims to prevent meningitis and ovarian cancer recurrence by generating immunity against specific bacteria.
A new study published in The Lancet Oncology found that imatinib treatment interruption after 3 years results in rapid relapse and low progression-free survival. Patients who stopped treatment experienced significant tumour growth and poor overall survival, highlighting the need for continuous treatment to maintain cancer control.
A new clinical trial found that MAGE-A3 ASCI reduces the risk of lung cancer relapse after surgery, similar to chemotherapy but with fewer side effects. The treatment, which boosts the immune system, showed minimal reactions at injection sites and was suitable for long-term maintenance treatment.
Researchers explored a new approach to maintenance therapy in patients with multiple myeloma, using pamidronate alone or in combination with thalidomide. The study found that ongoing treatment significantly improved cancer-free survival and overall survival probability compared to standard care.
Patients who quit smoking around cancer diagnosis have improved disease outcomes, better QOL, and prolonged survival compared to continuing smokers. Targeted interventions combining behavioral therapy and pharmacotherapy show promise in addressing individual barriers to cessation.
A new study found that slow recovery of normal white blood cells and high levels of leukaemic cells are predictive of relapse. The researchers discovered that these two factors predict outcome by distinct mechanisms, offering potential for personalized therapy adjustment.
A new test method aims to predict which early-stage cancer patients are at high risk for relapse, allowing for more precise treatment decisions. By analyzing apoptosis proteins in patient tumors, researchers hope to identify molecular and genetic signatures that indicate the likelihood of cancer recurrence.
A study by researchers at the H.Lee Moffitt Cancer Center has identified the ERCC1 gene as a potentially clinically useful independent marker for lung cancer. Patients with high levels of ERCC1 are more likely to survive after surgery and may benefit from platinum-based chemotherapy, while those with low levels have a poorer prognosis.
A research study found that pregnant women who receive supportive counseling are more likely to stay smoke-free, but relapse rates remain high. Ongoing counseling is necessary to prevent smoking relapse in postpartum women.